Paul Charles Knox
Institute of Ageing and Chronic Disease, University of Liverpool, UK
Title: Early detection of macular disease: AMD, DMO and beyond
Biography
Biography: Paul Charles Knox
Abstract
New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) have
transformed the prognosis for patients. But there is a pressing need for improved, cost-effective methods of detection and
monitoring of these conditions. The handheld radial shape discrimination (hRSD) test has shown potential for the early detection
of macular pathologies. We followed patients diagnosed with nAMD in their first eye, with no evidence of nAMD in their other eye
(study eye, SE) over consecutive, routine, clinic visits at which they undertook the hRSD test presented on an Apple iPod Touch.
We also examined hRSD test performance in patients referred from diabetic screening as being at risk of DMO (screening grade
M1). Of 179 nAMD patients, 19 (10.6%; “converters”) developed nAMD in the SE; hRSD thresholds in the converters began to
decline 190 days before diagnosis. At an hRSD cut-off of -0.60 logMAR, sensitivity was 0.79 (95% CI: 0.54–0.94) with a specificity
of 0.54 (0.46–0.62). Of 145 M1 patients, 44 (30.3%) were found to have centre involving macular oedema; hRSD thresholds were
significantly worse in these patients, compared both to those with no DMO and those with non-centre threatening DMO. Thus,
the hRSD test is sensitive, both to the earliest stages of pathology (in the nAMD patients) and to different stages of pathology (in
DMO). Given high levels of patient acceptability, that it can be done by patients away from clinics, and that it runs on inexpensive,
well connected devices, the hRSD test could have a role in both improved detection and monitoring of macular disease away from
hospital clinics.